miRNA生物合成相关基因的遗传变异与胃癌患者生存的关系

摘要

Objective To explore the relationship between genetic variants in miRNA machinery genes and outcomes in gastric cancer patients.Methods 96 patients with stage I-III gastric cancer treated with radical gastrectomy and adjuvant chemo-therapy of oxaliplatin and fluorouracils were analyzed.MassARRAY MALDI-TOF system was used to determine the genotypes.Re-sults The 2-year DFS rate was 60.5%and the 3-year OS rate was 73.2%.The 3-year OS was significantly different in patients with or without lymph node metastasis(63.7%vs 88.6%,P=0.017)and in patients with stage I-III disease(100.0%,87.9%and 56.9%,P=0.020.The 3-year OS for XPO5 rs11077 AA carriers was significantly higher than AC carriers(74.7% vs 64.8%,P=0.029).After the multi-variants' cox regression analysis,lymph node status and XPO5 rs11077 were found to be in-dependent prognostic factors for these patients.Conclusion XPO5 rs11077 could be associated with prognosis of gastric cancer patients treated with oxaliplatin and fluorouracils after surgical resection.%目的 研究miRNA生物合成相关基因的遗传变异与胃癌患者生存的关系.方法 96例接受奥沙利铂联合氟尿嘧啶类药物术后辅助化疗的Ⅰ ~Ⅲ期胃癌患者,分析 DICER rs13078,DICER rs3742330,RAN rs14035,XPO5 rs2257082,XPO5 rs11077遗传变异与患者无病生存期(DFS)和总生存期(OS)的相关性.结果 全组患者2年DFS为60.5%,3年OS为73.2%.淋巴结转移患者的3年OS显著低于无淋巴结转移患者,分别为63.7%和88.6%(P=0.017).临床分期与3年OS显著相关,Ⅰ、Ⅱ和Ⅲ期患者分别为100.0%、87.9%和56.9%(P=0.020).携带XPO5 rs11077 AC基因型患者的3年OS显著低于AA基因型患者,分别为64.8%和74.7%(P=0.029).多因素预后分析显示,淋巴结状态及XPO5 rs11077遗传变异为独立预后因素.结论 XPO5 rs11077遗传变异可能与胃癌患者预后相关.